https://eureka.patsnap.com/resources/blog/rd-blog/lentiviral-vector-manufacturing-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Lentiviral Vector Manufacturing
Lentiviral vector manufacturing patents: leaders, filing trends and open claim space
  • Filings peaked in 2021 at 436 and fell 47% to 231 by 2024, the last year the dataset treats as complete — a real pullback in new filing, not a data artefact.
  • The top 5 assignees hold 18.4% of all 5,157 records and the top 10 hold 29.8%, so more than two-thirds of the field sits with a long tail of single- or few-filing entrants.
  • C12N and A61K classes cover 79.7% and 64.3% of records respectively, meaning core vector construction and formulation claims are heavily occupied while adjacent process classes stay thin.
Get a prior-art report on your approach
5,157
Published Records
18%
Top-5 Share of All Records
-47%
Filing Growth 2021→2024
US
Leading Jurisdiction

Filing growth compares 2021 (436 records) with 2024 (231) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 5,157 records in scope (CR5), not by the ranked leaders only.

Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Field Overview

What the patent record shows about lentiviral vector manufacturing

Lentiviral vector manufacturing patents cluster around three practical problems: getting a packaging or producer cell line to hold a stable, high-titer output; choosing an envelope pseudotype that sets tropism without compromising particle stability; and controlling process variables — shear sensitivity, residual plasmid, transduction unit consistency — well enough to satisfy regulators. The search set spans 5,157 records filed or published between 2015 and mid-2026, drawing on classes for microorganism engineering, medicinal preparations and peptide chemistry rather than a single narrow art class.

Filing activity rose through the late 2010s, peaked in 2021, and has since declined through the last complete year on record. Publication lags filing by roughly 18 months, so 2025 and 2026 figures will keep filling in and should not yet be read as a trend reversal.

Annual filings, 2017-2026 (2026 partial)
  1. 1CITY OF HOPE217
  2. 2INST PASTEUR205
  3. 3FLAGSHIP PIONEERING INNOVATIONS VI LLC204
  4. 4THERAVECTYS163
  5. 5GENZYME CORP161
  6. 6RGT UNIV OF CALIFORNIA130
  7. 7TCR2 THERAPEUTICS INC128
  8. 8THE CLEVELAND CLINIC FOUND111
  9. 9NOVARTIS AG111
  10. 10TAKEDA PHARMA CO LTD105
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Lentiviral Vector Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Let an AI agent run this analysis on your own technology

Pick a task. Every answer cites the patents behind it.

10,000 free credits to start
Filing Data

Filing trends and technology composition

The filing curve and the IPC mix below are drawn directly from the 5,157 records in scope, using the same denominators throughout — no class share is computed against anything other than the full record count.

A 2021 peak followed by a real pullback

Filings ran from 261 in 2017 to a peak of 436 in 2021, then declined to 231 by 2024 — a 47% drop over that three-year span. Years after 2024 are still incomplete because of publication lag and should not be read against this figure.

A 2021 peak followed by a real pullback0125250375500261201720182019202043620212022202320242025182026Most recent year is partial — publication lag means later filings are not yet visible.

Core construction and formulation classes dominate

C12N (microorganisms and genetic engineering) appears on 79.7% of records and A61K (medicinal preparations) on 64.3%, confirming that most filings claim either the vector construct itself or its therapeutic formulation. C07K (peptides and proteins, 40.6%) and A61P (therapeutic activity, 25.9%) trail well behind. Process-adjacent classes — C12Q (5.7%), C12P (4.0%), C07H (4.1%) and C12R (3.1%) — are claimed far less often, which is where manufacturing-process detail tends to sit outside the core construct claims.

Core construction and formulation classes dominateC12N · Microorganisms & genetic engin…4,11279.7%A61K · Medicinal preparations3,31864.3%C07K · Peptides & proteins2,09440.6%A61P · Therapeutic activity of compou…1,33625.9%C12Q · Measuring & testing involving …2925.7%C07H · Sugars & nucleic acids2104.1%C12P · Fermentation & enzymatic synth…2044.0%C12R · Microorganisms (index)1603.1%Other4929.5%

Shares are the percentage of the 5,157 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Lentiviral Vector Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Lentiviral Vector Manufacturing with Eureka

This page is one run against one query. Ask Eureka your own question about lentiviral vector manufacturing and every answer comes back with the patent numbers behind it.

Try Eureka
Key Patents

Representative and most-cited filings

Representative Filing
US11299752B22022-04-12

US11299752B2 — Bio-production of lentiviral vectors

CSL BEHRING GENE THERAPY, INC.

The present disclosure provides a method of generating a stable producer cell line. The generation of stable producer cell lines, such as those provided in accordance with the present invention, increases the reproducibility and ease of creating high titer lentiviral stocks while easing biosafety concerns, and the variation in expressed envelope proteins defines the tropism of the generated virus. The present disclosure also provides for a novel lentiviral transfer vector plasmid.Filed by CSL Behring Gene Therapy and granted 2022-04-12, this filing sits squarely in the stable-producer-cell-line branch that the assignee ranking shows is contested rather than owned by a single leader.

US11299752B2 — patent drawing 1US11299752B2 — patent drawing 2
View full filing
Most-cited records in the lentiviral vector manufacturing set
#Publication no.Patent titleCitations
1US4861719ADNA constructs for retrovirus packaging cell lines1,200
2US5814482AEukaryotic layered vector initiation systems995
3WO1993025698A1Vector particles resistant to inactivation by human serum929
4WO1995007994A2Recombinant alphavirus vectors776
5WO1996017072A2Recombinant alphavirus vectors746
6WO1997009441A2Improved AAV vectors for gene therapy555
7US5843723AAlphavirus vector constructs511
8US5789245AAlphavirus structural protein expression cassettes495
9US6015686AEukaryotic layered vector initiation systems471
10WO1998017815A1Retroviral vectors353

Citation counts favour older filings inside any searched corpus; treat them as a signal of influence on downstream art, not as a ranking of current commercial relevance.

Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Lentiviral Vector Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the numbers mean for a filing decision

Three patterns stand out once the raw counts are read against each other: a real post-2021 pullback, a technology mix skewed toward construct and formulation claims, and a leadership picture that is concentrated at the very top but long-tailed everywhere else.

Filing Trend
-47%
2021 to 2024

The pullback from peak filing is real, not a lag artefact

Filings fell from 436 in 2021 to 231 in 2024, the last year the dataset treats as complete. That three-year decline predates the publication-lag window, so it reflects an actual reduction in new filing activity rather than records still working through the pipeline.

Read 2025-2026 figures as provisional.
Concentration
18.4% / 29.8%
top 5 / top 10 of 5,157 records

A handful of leaders, then a long tail

The top 5 ranked assignees combine for 18.4% of all 5,157 records and the top 10 for 29.8%. That leaves more than two-thirds of the corpus spread across the remaining ranked entrants and unranked filers, a structure that favours a freedom-to-operate search over assuming one player owns the space.

Ranking covers 100 assignees, not a top-50 cut.
Technology Mix
79.7% C12N
share of 5,157 records

Construct claims dominate; process claims are thin

C12N and A61K together sit on the large majority of records, showing that most applicants claim the vector construct or its formulation rather than downstream manufacturing steps. Classes tied to enzymatic and fermentation process control — C12Q, C12P, C07H, C12R — each sit under 6% of records.

Class shares overlap; a record can carry several.
Jurisdiction
1,137 US filings
of the tracked receiving offices

US and EPO lead filing venues, PCT close behind

The United States receives the largest single share of filings tracked (1,137), followed by the EPO (816) and WIPO/PCT (787), with Australia, Israel and Canada some way behind. That order is typical of a biologics field where applicants file nationally in the largest markets while keeping a PCT option open.

Counts are by receiving office, not by family.
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to lentiviral vector manufacturing, with the prior art for and against each one.

Find the white space →
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Lentiviral Vector Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Who's Filing

Leaders, collaborators and where momentum is shifting

The assignee ranking covers 100 companies and institutions counted by patent family. Leadership is concentrated at the very top but thins quickly, and recent-year momentum data suggests most of the historic leaders have gone quiet in the most recent tracked year — consistent with the broader post-2021 pullback rather than any single company's retreat.

Leader
217 records
leading assignee

One clear leader, a narrow gap to fifth

The leading assignee holds 217 records against 161 for the fifth-placed entrant and 105 for tenth — a steep but not runaway drop-off, indicating an active but not monopolised leadership tier.

Counted in patent families.
Collaboration
130 co-filings
strongest assignee pair

Research institutes anchor the densest collaboration pair

The strongest co-assignee pairing in the dataset spans 130 shared records, with two further pairings at 64 and 46. All three of the strongest pairs involve the same French research institute, pointing to an academic-industry cluster rather than isolated joint ventures.

10 co-assignee pairs tracked in total.
Momentum
-88% to -100%
YoY, most tracked leaders

Most historic leaders show near-zero activity in the latest year

Recent-year momentum for several previously active assignees — universities, research institutes and a gene-therapy specialist among them — shows year-on-year declines approaching or at -100%, echoing the field-wide drop from the 2021 peak rather than signalling any single firm's exit.

Latest year is still partial; treat as provisional.
🔍
Under-claimed sub-areas worth a closer freedom-to-operate look
Process-adjacent classes carry a fraction of the filing density seen in construct and formulation claims — that gap is where a narrowly drafted claim is more likely to clear prior art.
Closed-system bioreactor shear controlResidual plasmid clearance methodsEnvelope pseudotyping stability at scaleProducer cell line genomic stability assaysDownstream transduction unit potency testing
Rank all filers by momentum →
Recent-year filing momentum by assignee
AssigneeRecent yearYoY
Novartis AG2+100%
The Regents of the University of California1-88%
City of Hope0-100%
Flagship Pioneering Innovations VI, LLC0-100%
Institut Pasteur0-100%
Genzyme Corp0-100%
Theravectys0-100%
TCR2 Therapeutics Inc0—
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Lentiviral Vector Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next

Where to take this analysis next

The dataset points to a field with occupied core claims and thinner process-side coverage. Two follow-on steps make that actionable.

Run a freedom-to-operate check against the top 10 assignees

With 29.8% of records held by ten entrants, a targeted FTO search against just those filers covers a meaningful share of the risk before widening to the full ranked list.

Explore assignee claims in Eureka

Map process-class claims against the construct-class leaders

Because C12Q, C12P, C07H and C12R each sit under 6% of records, a claim drafted tightly around process control is less likely to collide with the dense C12N and A61K filings.

Map white space in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Lentiviral Vector Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Frequently asked questions

Answers are grounded in the same dataset. Derived from a Patsnap search on Lentiviral Vector Manufacturing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Lentiviral Vector Manufacturing in depth with Eureka

Go past this page: query the whole lentiviral vector manufacturing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.